{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:39Z","timestamp":1791950919861,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Children without Down syndrome or acute promyelocytic leukemia who were newly diagnosed with primary myelodysplastic syndrome or acute myeloid leukemia (AML) M6 or M7 were compared to children with de novo AML M0\u2013M5. All children were entered on the Children's Cancer Group therapeutic research study CCG 2891.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The presentation and outcomes of the 132 children diagnosed with MDS (60 children), AML FAB M6 (19 children), or AML FAB M7 (53 children) were similar. Children with AML FAB M7 were diagnosed at a significantly younger age (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). Children with MDS, M6, or M7 had significantly lower white blood cell (WBC) counts (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), lower peripheral blast counts (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and an increased frequency of \u22127\/7q\u2010 (<jats:italic>P<\/jats:italic>\u2009=\u20090.003) at presentation. All three groups had significantly inferior overall survival (OS) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and event free survival (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) compared with the 748 children diagnosed with AML FAB M0\u2013M5 when assessed from entry on study. This poor survival was largely attributable to induction death and failure. However, when assessed from successful completion of induction therapy, the 5\u2010year OS (<jats:italic>P<\/jats:italic>\u2009=\u20090.090)(49.1 vs. 56.9%) and disease\u2010free survival (DFS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.113)(38.0 vs. 46.3%) therapy were not significantly different from other children with AML.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Childhood AML FAB M6 and AML M7 resemble MDS in presentation, poor induction success rates, and outcomes. Pediatr Blood Cancer 2007;49:17\u201322. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20951","type":"journal-article","created":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T19:41:53Z","timestamp":1153338113000},"page":"17-22","source":"Crossref","is-referenced-by-count":73,"title":["Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group"],"prefix":"10.1002","volume":"49","author":[{"given":"Dorothy R.","family":"Barnard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,5,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood.V87.12.4979.bloodjournal87124979","article-title":"Timed\u2010sequential induction therapy improves post\u2010remission outcome in acute myeloid leukemia [AML]: A report from the Children's Cancer Group","volume":"87","author":"Woods WG","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07532.x"},{"key":"e_1_2_5_4_2","first-page":"1826","article-title":"Revised classification of acute myeloid leukemia","volume":"10","author":"Head DR","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-3-460"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04444.x"},{"key":"e_1_2_5_9_2","first-page":"5","article-title":"Morphologic, immunologic and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: A report from the Childrens Cancer Group","volume":"10","author":"Barnard DR","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/110.5.590"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.2.434"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402765"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.V56.2.318.318","article-title":"Chromosome marker evidence for the bipotentiality of BFU\u2010E","volume":"56","author":"McLeod DL","year":"1980","journal-title":"Blood"},{"key":"e_1_2_5_14_2","first-page":"1316","article-title":"Megakaryocytic and erythrocytic cell lines share a common precursor cell","volume":"21","author":"McDonald TP","year":"1993","journal-title":"Exp Hematol"},{"key":"e_1_2_5_15_2","first-page":"391","article-title":"Thrombopoietin expands erythroid progenitors, increases red cell production and enhances erythroid recovery after myelosuppressive therapy","volume":"85","author":"Kaushansky K","year":"1995","journal-title":"J Clin Invest"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.40.6.663"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830490106"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0320(20010215)46:1<23::AID-CYTO1033>3.0.CO;2-Z"},{"key":"e_1_2_5_19_2","first-page":"259","article-title":"Limits of phenotypic markers for the diagnosis of megakaryoblastic leukemia","volume":"15","author":"Breton\u2010Gorius J","year":"1989","journal-title":"Blood Cells"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00904.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05591.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/344447a0"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1284.bloodjournal8841284"},{"key":"e_1_2_5_24_2","first-page":"2879","article-title":"Cellular drug resistance profiles in childhood acute myeloid leukemia: Differences between FAB types and comparison with acute lymphoblastic leukemia","volume":"96","author":"Zwaan CM","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_25_2","first-page":"425","article-title":"Uncommon subtypes of acute nonlymphocytic leukemia: Clinical features and management of FAB M5, M6 and M7","volume":"14","author":"Peterson BA","year":"1987","journal-title":"Semin Oncol"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0925-5710(96)00455-0"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400558"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200004)63:4<212::AID-AJH9>3.0.CO;2-D"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3444"},{"key":"e_1_2_5_30_2","first-page":"1269","article-title":"Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia","volume":"10","author":"Hasle H","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400987"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03369.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402271"},{"key":"e_1_2_5_34_2","first-page":"S33","article-title":"Megakaryoblastic disorders in children","volume":"122","author":"Lorsbach RB","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148552"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3727"},{"key":"e_1_2_5_37_2","first-page":"2405","article-title":"Acute megakaryocytic leukemia: The Eastern Cooperative Oncology Group experience","volume":"96","author":"Tallman MS","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1714"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3064"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11313"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02328.x"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402340"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0137"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0578"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05167.x"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20951","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T21:37:10Z","timestamp":1696887430000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,22]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1002\/pbc.20951"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20951","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,22]]}}}